AI assistant
HAEMONETICS CORP — Director's Dealing 2011
May 4, 2011
31565_dirs_2011-05-04_17a4298b-f6b9-40f1-b47c-1ec5bc9e9bba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2011-05-04
Reporting Person: Brancazio Phillip John (VP, Global Manufacturing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-05-04 | Common Stock | P | 67.0 | $46.801 | Acquired | 3052.0 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $52.94 | 2016-10-27 | Common Stock (12242.0) | 12242.0 | Direct |
| Non-Qualified Stock Option (right to buy) | $54.99 | 2017-10-27 | Common Stock (11837.0) | 11837.0 | Direct |
| Non-Qualified Stock Option (right to buy) | $58.64 | 2016-07-29 | Common Stock (11441.0) | 11441.0 | Direct |
Footnotes
F1: Acquisition of shares of Common Stock pursuant to the Employee Stock Purchase Plan. Participant elected to purchase shares at least six months in advance of the effective date of the transaction.
F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.